Neurologic Complications, Reoperation, and Clinical Outcomes following Surgery for XXXX .

@entity1 @entity4034 @entity16 @entity51 @entity158
STUDY DESIGN: A consecutive retrospective cohort study from 2008 to 2013 at a single tertiary-care institution was conducted. OBJECTIVE: Characterize recovery from @entity51 after surgical for @entity4034 , and identify incidence of postoperative adverse events. SUMMARY OF BACKGROUND DATA: A minority of @entity1 with @entity4034 require surgery. While prior studies have characterized outcomes after medical management, the morbidity after surgery is poorly defined. METHODS: The primary outcome was change from baseline in a Modified McCormick Scale (MMS, 1-5 scale), while secondary outcomes included reoperation and change in self-reported @entity158 Visual Analog Scale (VAS, 0-10 scale).MMS and VAS were collected throughout the postoperative course as surrogates for neurologic function and degree of @entity158 . Intraoperative, short-term postoperative (<30 days), and long-term neurologic complications were recorded. New-onset @entity51 in the postoperative period were considered neurologic complications. RESULTS: Fifty @entity1 were included; a majority (52%) presented with a @entity51 . The median length of follow-up was 18 months. A statistically significant improvement in MMS was observed by 12 months postoperatively, while an improvement in VAS was observed by 3 months. The mean improvement in MMS at last follow-up was 0.35, while the mean improvement in VAS was 3.40. One quarter of @entity1 required reoperation. At 24 months postoperatively, 10% died, 26% underwent reoperation, 42% experienced a @entity16 , and 60% experienced at least one of these three adverse events. CONCLUSIONS: This is the first study to investigate neurologic complications, reoperation, and @entity158 in a longitudinal manner following surgery for VO. We observed statistically significant improvements in MMS and VAS in the postoperative period. Despite these improvements, the 24-month incidence of overall adverse events was 60%. @entity1 and clinicians should be aware of the clinical improvement but high incidence of adverse events following surgical management of VO. LEVEL OF EVIDENCE: 4.
